Search This Blog

1

Labels

Cancer (150) Breast (38) Study (38) Health (32) Patients (31) Treatment (27) Could (23) Therapy (19) Research (17) Against (12) Blood (11) Disease (11) linked (11) Diabetes (10) Early (10) Prevent (10) Survival (10) Treatments (7) higher (7) surgery (7) Might (6) Prostate (6) Tumors (6) During (5) Effects (5) Growth (5) Chemotherapy (4) Drinking (4) Prevention (4) Obama (3) Obesity (3) Without (3) associated (3) Experts (2) Important (2) Infection (2) About (1) Analysis (1) Causes (1) Eliminate (1) stroke (1)

AD

Showing posts with label genome. Show all posts
Showing posts with label genome. Show all posts

Monday, September 30, 2013

On the other side of the cancer genome benefits

Cancer is not single entity rather it asks complex diseases over a hundred distinct and unique treatment strategies and types of cancer. Pan TCGA researchers have developed a formal analysis of cancer is called cross-project. Whose goal is assembled of TCGA data beyond the type of tumor and interpret their data and analysis, at the end, both the analysis and data freely available.

View the original article here

Wednesday, September 18, 2013

Host genome controls skin microbiota and inflammation

Sep. 17, 2013 — Numerous recent studies linked gut microbiota with various diseases such as obesity or diabetes. Little is known, however, on how gut and skin microbiota composition is controlled. In a recent study published in the journal Nature Communications on 17 September, John Baines, Saleh Ibrahim and their colleagues of the Inflammation Research Excellence Cluster show that composition of skin microbiota is controlled by the host genome and that skin bacteria may have a greater influence on inflammatory diseases than previously thought. Their landmark findings will open the door to identify gene variants controlling skin microbiota and to define their link to various diseases such as skin inflammatory disorders.

The human body contains more bacteria than human cells. Most of these bacteria comprise the normal gut and skin microbiota. Susceptibility to chronic inflammatory diseases is determined by immunogenetic and environmental risk factors that include resident microbial communities. Whether these differences are of primary etiological importance or secondary to the altered inflammatory environment remains largely unknown.

The inflammation cluster research groups led by Saleh Ibrahim of the University of Lubeck, and John Baines of the MPI and CAU, correlated the genomic variations of hundreds of mice that partially develop skin inflammatory diseases with skin microbiota. They showed evidence for host gene-microbiota interactions contributing to disease risk in a mouse model of autoantibody-induced inflammatory skin disease. Furthermore they identified genetic loci contributing to skin microbiota variability, susceptibility to skin inflammation and their overlap. The majority of the identified microbiotal communities are characterized by reduced abundance being associated with increased disease risk, providing evidence of a primary role in protection from disease.

These findings offer a promising potential for using those probiotic species for preventative and therapeutic treatment development. John Baines: "It appears that the skin flora is a phenotype that is partially controlled by the host genome variations. This in turn predisposes to the development of disease. The more we learn about these interactions, the more possibilities there will be for a better and more individualized treatment and prevention of skin inflammatory diseases.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is based on materials provided by Christian-Albrechts-Universitaet zu Kiel.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Girish Srinivas, Steffen Moller, Jun Wang, Sven Kunzel, Detlef Zillikens, John F. Baines, Saleh M. Ibrahim. Genome-wide mapping of gene–microbiota interactions in susceptibility to autoimmune skin blistering. Nature Communications, 2013; 4 DOI: 10.1038/ncomms3462

Note: If no author is given, the source is cited instead.


View the original article here

Friday, June 22, 2012

GSK extends its $2.6 billion offer for Human Genome

AppId is over the quota
AppId is over the quota

LONDON (Reuters) - GlaxoSmithKline has extended its $2.6 billion offer to buy long-time partner Human Genome Sciences until the end of June as it battles the U.S. biotech company's reluctant management.

The price remains unchanged at $13 a share under the longer tender, which will now expire at 5 p.m. EDT (2100 GMT) New York time on June 29, Britain's biggest drugmaker said on Friday.

The initial tender period ran out at midnight on June 7, by when GSK had secured less than 1 percent of Human Genome shares, which are trading at a premium to its offer.

People familiar with the situation had previously told Reuters that GSK was set to extend its tender offer - a direct appeal to Human Genome shareholders over the heads of management - as it begins a process to replace the entire Human Genome board with its own nominees.

The British company has already started reaching out to executives in the drug industry as well as finance and governance experts who could be nominated as independent directors of the 12-member board.

Sources said on May 30 that GSK intended to seek approval from Human Genome shareholders to replace the board under a "consent solicitation" process, which could come in the next few weeks. No details on the process were given on Friday.

Human Genome once again rejected GSK's bid as inadequate. It has launched an auction process, inviting GSK to participate, while at the same time adopting a "poison pill" shareholder rights plan in a bid to thwart the hostile takeover attempt.

The U.S. firm has had contacts with other companies and said on Friday that the process "continues to be active and fully underway". But no counterbidder to GSK has emerged and bankers say GSK has an advantage over rivals because of its partnerships around key drugs.

The two companies together sell Benlysta, a new drug for the autoimmune condition lupus, and they also collaborate on two other experimental drugs for diabetes and heart disease that could become significant sellers. GSK and Human Genome share rights to Benlysta, while GSK owns the majority of the commercial upside to the other products.

Buying Human Genome would give GSK full rights to these partnered drugs, underscoring the appetite among big drugmakers for biotech products to refill their medicine chests.

But GSK may have more work to do in persuading investors that its $13-per-share bid is good enough and shares in Human Genome traded 2 percent higher at $13.50 by 1430 GMT.

That indicates investors still expect a higher price, although the stock has fallen back from a high of more than $15 hit in April, soon after the unsolicited offer was made public.

(Editing by Kate Kelland and Hans-Juergen Peters)